產(chǎn)品訂購(gòu)信息：
英文名稱  Anti-ROC1/RNF75 

中文名稱   環(huán)指蛋白75抗體費(fèi)用 

別    名  E3 ubiquitin-protein ligase RBX1; MGC13357; MGC1481; Protein ZYP; Rbx 1; Rbx1; RBX1_HUMAN; Regulator of Cullins 1; Ring box 1; RING box protein 1; RING finger protein 75; RING finger protein; RING-box protein 1; Ringbox protein 1; RNF 75; RNF75; ROC 1; ZYP protein.

濃    度   1mg/1ml

規(guī) 格  0.2ml/200μg

抗體來(lái)源   Rabbit

克隆類型   polyclonal

交叉反應(yīng)   Human, Mouse, Rat, Cow 

產(chǎn)品類型   一抗  

研究領(lǐng)域    細(xì)胞生物 免疫學(xué) 表觀遺傳學(xué)

蛋白分子量  predicted molecular weight: 12kDa

性    狀   Lyophilized or Liquid

免 疫 原 KLH conjugated synthetic peptide derived from human ROC1/RNF75 

亞    型   IgG

純化方法   affinity purified by Protein A

儲(chǔ) 存 液   Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4

環(huán)指蛋白75抗體費(fèi)用 產(chǎn)品應(yīng)用    WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:50-200

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 E3 ubiquitin ligase component of multiple cullin-RING-based E3 ubiquitin-protein ligase complexes which mediate the ubiquitination and subsequent proteasomal degradation of target proteins, including proteins involved in cell cycle progression, signal transduction, transcription and transcription-coupled nucleotide excision repair. The functional specificity of the E3 ubiquitin-protein ligase complexes depends on the variable substrate recognition components. As a component of the CSA complex promotes the ubiquitination of ERCC6 resulting in proteasomal degradation. Through the RING-type zinc finger, seems to recruit the E2 ubiquitination enzyme, like CDC34, to the complex and brings it into close proximity to the substrate. Probably also stimulates CDC34 autoubiquitination. May be required for histone H3 and histone H4 ubiquitination in response to ultraviolet and for subsequent DNA repair. Promotes the neddylation of CUL1, CUL2, CUL4 and CUL4 via its interaction with UBE2M.

Function : E3 ubiquitin ligase component of multiple cullin-RING-based E3 ubiquitin-protein ligase complexes which mediate the ubiquitination and subsequent proteasomal degradation of target proteins, including proteins involved in cell cycle progression, signal transduction, transcription and transcription-coupled nucleotide excision repair. The functional specificity of the E3 ubiquitin-protein ligase complexes depends on the variable substrate recognition components. As a component of the CSA complex promotes the ubiquitination of ERCC6 resulting in proteasomal degradation. Through the RING-type zinc finger, seems to recruit the E2 ubiquitination enzyme, like CDC34, to the complex and brings it into close proximity to the substrate. Probably also stimulates CDC34 autoubiquitination. May be required for histone H3 and histone H4 ubiquitination in response to ultraviolet and for subsequent DNA repair. Promotes the neddylation of CUL1, CUL2, CUL4 and CUL4 via its interaction with UBE2M. Involved in the ubiquitination of KEAP1, ENC1 and KLHL41.

Subunit : Part of a SCF complex consisting of CUL1, RBX1, SKP1 and SKP2. Part of a SCF-like complex consisting of CUL7, RBX1, SKP1 and FBXW8. Part of CBC(VHL) complexes with elongin BC complex (TCEB1 and TCEB2), CUL2 or CUL5 and VHL. Part of the CSA complex (DCX(ERCC8) complex), a DCX E3 ubiquitin-protein ligase complex containing ERCC8, RBX1, DDB1 and CUL4A; the CSA complex interacts with RNA polymerase II; upon UV irradiation it interacts with the COP9 signalosome and preferentially with the hyperphosphorylated form of RNA polymerase II. Part of multisubunit E3 ubiquitin ligase complexes with elongin BC complex (TCEB1 and TCEB2), CUL2 and MED8; elongin BC complex (TCEB1 and TCEB2), CUL5 and MUF1. Part of multisubunit complexes with elongin BC complex (TCEB1 and TCEB2), elongin A/TCEB3 or SOCS1 or WSB1 and CUL5. Interacts directly with CUL1 and probably also with CUL2, CUL3, CUL4A, CUL4B, CUL5 and CUL7. Probably interacts with CDC34. Interacts with COPS6. Component of the DCX DET1-COP1 ubiquitin ligase complex at least composed of RBX1, DET1, DDB1, CUL4A and COP1. Part of an E3 ligase complex composed of RBX1, DDB1, DDB2 and CUL4A or CUL4B. Interacts with UBE2M. Part of a SCF complex consisting of CUL1, FBXO3, RBX1 and SKP1; this complex interacts with PML via FBXO3. Interacts with human adenovirus early E1A protein; this interaction inhibits RBX1-CUL1-dependent elongation reaction of ubiquitin chains by the SCF(FBW7) complex. Component of the SCF(Cyclin F) complex consisting of CUL1, RBX1, SKP1 and CCNF. Identified in a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin ligase complex together with HINT1 and CDC34. Component of multiple BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complexes formed of CUL3, RBX1 and a variable BTB domain-containing protein. Part of the BCR(ENC1) complex containing ENC1. Part of the BCR(GAN) complex containing GAN. Part of the BCR(KLHL41) complex containing KLHL41. Part of the BCR(KEAP1) complex containing KEAP1.

Subcellular Location : Cytoplasm. Nucleus.

Tissue Specificity : Widely expressed.

Similarity : Belongs to the RING-box family.

Contains 1 RING-type zinc finger.

Database links : UniProtKB/Swiss-Prot: P62877.1

GRB2/ASH peptide 生長(zhǎng)因子受體結(jié)合蛋白2抗原Multi-class antibodies規(guī)格： 0.5mg

Oct4 Oct4 鼠單抗 (FITC) Human

Rhesus antibody Rh phospho-CstF64(Ser498) 磷酸化細(xì)胞分裂相關(guān)蛋白CSTF64抗體 規(guī)格 0.1ml

染色液 100ml 自產(chǎn)

ZNF704 英文名稱： 鋅指蛋白704抗體 0.2ml

DCUN1D2 英文名稱： DCN1樣蛋白2抗體 0.2ml

Oct4 Oct4 鼠單抗 (FITC) Human

ATEXPA10 peptide 植物擴(kuò)張蛋白ATEXPA10(擬南芥)抗原Multi-class antibodies規(guī)格： 0.5mg

抗磷酸化Bcl-xL(pSer62)蛋白抗體 Anti-phospho-Bcl-xL 0.1ml

Rhesus antibody Rh phospho-EGFR (Ser1166) 磷酸化表皮生長(zhǎng)因子受體抗體 規(guī)格 0.1ml

DMEM高糖 10×1L Gibco

ZNF740 英文名稱： 鋅指蛋白740抗體 0.2ml

DYRK3 英文名稱： 雙特異性酪酸磷酸化調(diào)節(jié)激酶3抗體 0.2ml

抗磷酸化Bcl-xL(pSer62)蛋白抗體 Anti-phospho-Bcl-xL 0.1ml

phospho-ZCWCC1 (Ser739) 英文名稱： 磷酸化ZCWCC1抗體 0.1ml

DSPP 英文名稱： 牙本質(zhì)磷蛋白抗體 0.1ml

APP淀粉樣肽前體蛋白抗體 Anti-APP/Amyloid beta A4 0.1ml

Anti-AFP/HRP 辣根過(guò)氧化物酶標(biāo)記鼠抗人甲胎蛋白單克隆抗體(檢測(cè))IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh Phospho-eNOS(Thr495) 磷酸化合成酶3抗體(內(nèi)皮型) 規(guī)格 0.1ml

Nadrin peptide 發(fā)育調(diào)節(jié)蛋白多肽抗原Multi-class antibodies規(guī)格： 0.5mg

TNFSF8 Protein Rat 重組大鼠 CD153 / CD30L / TNFSF8 蛋白 (Fc 標(biāo)簽)

EC9706

LIF Others Mouse 小鼠 LIF 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)

SW620人細(xì)胞 SW620 human colon cancer cells L-15+10%FBS

人上皮細(xì)胞;Hep-2

人胚胎絨毛細(xì)胞(HAF)(1×106 ) 細(xì)胞名稱 種屬

CL-0430RS1(大鼠皮膚成纖維樣細(xì)胞)5×106cells/瓶×2

IL22RA1 Others Canine 狗 IL22RA1 / IL22R 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)

人食道上皮細(xì)胞RNAHEEpiC miRNA5 μg

兔間變表皮鱗株;VX2 細(xì)胞，22RV1細(xì)胞 MDCK superdome細(xì)胞，狗腎細(xì)胞隆突型

人永生化淋巴細(xì)胞;CNLMG-B5537LC

HA Others H3N2 甲型 H3N2 (A/Aichi/2/1968) 血凝素HA1 (Hemagglutinin) 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)

環(huán)指蛋白75抗體費(fèi)用 TNFSF8 Protein Rat 重組大鼠 CD153 / CD30L / TNFSF8 蛋白 (Fc 標(biāo)簽)

EC9706

LIF Others Mouse 小鼠 LIF 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)

SW620人細(xì)胞 SW620 human colon cancer cells L-15+10%FBS

人上皮細(xì)胞;Hep-2

人胚胎絨毛細(xì)胞(HAF)(1×106 ) 細(xì)胞名稱 種屬

抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn)：

1. 環(huán)指蛋白75抗體費(fèi)用 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對(duì) 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；

2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來(lái)篩選最適條件；

3.用NHSB量過(guò)量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；

4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等；

5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性；

6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價(jià)結(jié)合；

7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會(huì)對(duì)生物素化抗體與親和素的結(jié)合產(chǎn)生競(jìng)爭(zhēng)作用；

8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對(duì)某些細(xì)胞可導(dǎo)致高本底。

抗體的鑒定：

1）環(huán)指蛋白75抗體費(fèi)用 抗體的效價(jià)鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來(lái)鑒定。

2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識(shí)別能力?？贵w的特異性高,它的識(shí)別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來(lái)表示。交叉反應(yīng)率可用競(jìng)爭(zhēng)抑制試驗(yàn)測(cè)定。以不同濃度抗原和近似抗原分別做競(jìng)爭(zhēng)抑制曲線,計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。 

如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無(wú)窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。

3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫(kù)侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測(cè)定對(duì)抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。